INVA · Innoviva, Inc.

Innoviva reported Q1 2026 revenue of $98.0 million, up 10.6% from $88.6 million in the prior year quarter. This growth occurred as higher product sales volumes countered headwinds in royalty revenues. Management noted that the decrease in total net royalty revenue stemmed primarily from lower net sales due to pricing pressures in the United States. Meanwhile, product sales benefited from an interim supply agreement with Zai Lab, billed at cost, which contributed to the overall revenue increase but also elevated associated costs.

Gross profit reached $75.8 million, a 3.4% improvement from $73.3 million, yielding a gross margin of 77.4%. The modest profit growth reflected higher cost of products sold, driven by increased product sales volume as highlighted in management's discussion. This dynamic underscores how volume expansion in critical care products like GIAPREZA and XACDURO supported topline growth but compressed margins at the gross level due to the cost structure of these sales.

Operating income fell 7.9% to $38.2 million from $41.4 million, with the operating margin at 38.9%. The decline resulted from the combination of higher cost of goods tied to sales volume and increased selling, general, and administrative expenses likely related to promotional efforts. These pressures illustrate the trade-offs in Innoviva's strategy to drive product sales growth amid royalty challenges, maintaining solid but reduced operating profitability.

The standout result was net income of $186.6 million, a dramatic turnaround from a $46.6 million loss in Q1 2025, delivering diluted EPS of $2.22 versus -$0.74. This transformation was powered by substantial non-operating gains, including equity method investment income and fair value adjustments on long-term investments. Such gains, while non-recurring in nature, highlight Innoviva's strategic investments in healthcare opportunities where its experience can drive returns, significantly boosting headline profitability.